Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Experimental Hematology & Oncology
|
December 26, 2022
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients
Ming Yi, Di Zhang, Bin Song, et al.
Molecular Cancer
|
November 26, 2023
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Journal for Immunotherapy of Cancer
|
December 2, 2022
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, et al.
Science China. Life Sciences
|
November 7, 2025
Development and application of antibody-drug conjugates in gynecological cancers
Ruxi Zheng, Jiaojiao Zhang, Jianwei Zhou, et al.
Journal of Hematology & Oncology
|
February 17, 2021
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Ming Yi, Jing Zhang, Anping Li, et al.
Journal of Hematology & Oncology
|
September 16, 2021
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
Ming Yi, Mengke Niu, Jing Zhang, et al.
Journal of Hematology & Oncology
|
March 5, 2025
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis
Yuze Wu, Yuheng Yan, Yarong Guo, et al.
Journal of Hematology & Oncology
|
October 8, 2022
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu, et al.
Journal of Hematology & Oncology
|
August 12, 2023
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Mengke Niu, Ming Yi, Yuze Wu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
September 20, 2024
Blockade of CCR5<sup>+</sup> T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody
Ming Yi, Tianye Li, Mengke Niu, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Experimental Hematology & Oncology
|
December 26, 2022
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients
Ming Yi, Di Zhang, Bin Song, et al.
Molecular Cancer
|
November 26, 2023
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Journal for Immunotherapy of Cancer
|
December 2, 2022
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, et al.
Science China. Life Sciences
|
November 7, 2025
Development and application of antibody-drug conjugates in gynecological cancers
Ruxi Zheng, Jiaojiao Zhang, Jianwei Zhou, et al.
Journal of Hematology & Oncology
|
February 17, 2021
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Ming Yi, Jing Zhang, Anping Li, et al.
Journal of Hematology & Oncology
|
September 16, 2021
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
Ming Yi, Mengke Niu, Jing Zhang, et al.
Journal of Hematology & Oncology
|
March 5, 2025
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis
Yuze Wu, Yuheng Yan, Yarong Guo, et al.
Journal of Hematology & Oncology
|
October 8, 2022
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu, et al.
Journal of Hematology & Oncology
|
August 12, 2023
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Mengke Niu, Ming Yi, Yuze Wu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
September 20, 2024
Blockade of CCR5<sup>+</sup> T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody
Ming Yi, Tianye Li, Mengke Niu, et al.
Page
of 4